Discovery and validation of autosomal dominant Alzheimer’s disease mutations
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes. METHODS: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses. RESULTS: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379_382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity. CONCLUSIONS: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Self-citationQuantitative Analysis of PiB-PET with FreeSurfer ROIs
Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246
Self-citationRare autosomal copy number variations in early-onset familial Alzheimer’s disease
Hooli, B. V., Kovacs-Vajna, Z. M., Mullin, K., Blumenthal, M. A., Mattheisen, M., Zhang, C., Lange, C., Mohapatra, G., Bertram, L., & Tanzi, R. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.77 · Cited by 100
Sala Frigerio, C., Lau, P., Troakes, C., Deramecourt, V., Gele, P., Van Loo, P., Voet, T., & De Strooper, B. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.007 · Cited by 71
Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152082 · Cited by 56
Self-citation
Cited by
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Xiao, X., Liu, H., Liu, X., Zhang, W., Zhang, S., & Jiao, B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.695808 · Cited by 99
Reelin links Apolipoprotein E4, Tau, and Amyloid‐β in Alzheimer’s disease
Yi, L. X., Zeng, L., Wang, Q., Tan, E. K., & Zhou, Z. D. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102339 · Cited by 41
Llibre-Guerra, J. J., Fernandez, M. V., Joseph-Mathurin, N., Bian, S., Carter, K., Li, Y., Aschenbrenner, A. J., Pottier, C., Sigurdson, W., McDade, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03494-0 · Cited by 28
“Here, we report the longitudinal clinical in vivo neuroimaging and biofluid biomarkers follow-up of an exceptional resilience mutation carrier who inherited a known pathogenic mutation in the PSEN2 gene (p.Asn141Ile) 12–16 but is 18 years past the expected AAO.”
Self-citationEvaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2
Marsh, J. A., Huang, G., Bowling, K., Renton, A. E., Ziegemeier, E., Ball, T., Pottier, C., Cruchaga, C., Day, G. S., Bateman, R. J., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00527 · Cited by 9
“We have tested more than 100 VUS in APP , PSEN1 , and PSEN2 [1,22,23], and we have not yet identi fi ed a VUS with discordant evidence between the family pedigree and cell-based assay.”
Self-citation
Metadata
- Authors
- Dominantly Inherited Alzheimer Network (DIAN), Hsu, S., Gordon, B. A., Hornbeck, R., Norton, J. B., Levitch, D., Louden, A., Ziegemeier, E., Laforce, R., Chhatwal, J., Day, G. S., McDade, E., Morris, J. C., Fagan, A. M., Benzinger, T. L. S., Goate, A. M., Cruchaga, C., Bateman, R. J., & Karch, C. M.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 1
- Pages
- 67-67
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2883056534
- Cited by
- 49
- References
- 5
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and validation of autosomal dominant Alzheimer’s disease mutations. https://app.cochat.ai/papers/10.1186/s13195-018-0392-9
- The paper
- Dominantly Inherited Alzheimer Network (DIAN), Hsu, S., Gordon, B. A., Hornbeck, R., Norton, J. B., Levitch, D., Louden, A., Ziegemeier, E., Laforce, R., Chhatwal, J., Day, G. S., McDade, E., Morris, J. C., Fagan, A. M., Benzinger, T. L. S., Goate, A. M., Cruchaga, C., Bateman, R. J., & Karch, C. M. (2018). Discovery and validation of autosomal dominant Alzheimer’s disease mutations. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-018-0392-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.